GUIDELINES FOR AN INTEGRATED DIAGNOSTIC APPROACH OF CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ROUTINE LABORATORY OF HAEMATOLOGY IN BELGIUM

REFERENCES

• Van Bockstaele DR, Deneys V, Philippe J, et al: Belgian consen-sus recommendations for flow cytometric immunophenotyp-ing. The Belgian Association for Cytometry/Belgische Verenig-ing voor Cytometrie/Association Belge de Cytometrie. Acta Clin Belg 1999; 54(2):88–98.
   PubMedGoogle Scholar
• Schenker EL, Hutin LE, Bauer KD, Ferbas J, Margolick JB, Giorgi JV: Evaluation of a dual-color flow cytometry immunopheno-typing panel in a multicenter quality assurance program. Cy-tometry 1993; 14(4307–317.
   Google Scholar
• Bain BJ, Barnett D, Linch D, Matutes E, Reilly JT: Revised guideline on immunophenotyping in acute leukaemias and chronic lym-phoproliferative disorders. Clin Lab Haematol 2002; 24(1):1–13.
   PubMedGoogle Scholar
• Braylan RC, Orfao A, Borowitz MJ, Davis BH: Optimal number of reagents required to evaluate hematolymphoid neoplasias: re-sults of an international consensus meeting. Cytometry 2001; 46(1):23–27.
   PubMedGoogle Scholar
• Stelzer GT, Shults KE, Loken MR: CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann N Y Acad Sci 1993; 677:265–280.
   PubMed Web of Science ®Google Scholar
• Costa ES, Arroyo ME, Pedreira CE, et al: A new automated flow cytometry data analysis approach for the diagnostic screening of neoplastic B-cell disorders in peripheral blood samples with absolute lymphocytosis. Leukemia 2006; 20(7)1221–1230.
   PubMed Web of Science ®Google Scholar
• Neumaier M, Braun A, Wagener C: Fundamentals of quality as-sessment of molecular amplification methods in clinical diag-nostics. International Federation of Clinical Chemistry Scien-tific Division Committee on Molecular Biology Techniques. Clin Chem 1998; 44(1)12–26.
   PubMedGoogle Scholar
• Moreau EJ, Matutes E, A'Hern RP, et al: Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody 5N8 (CD79b). Am] Clin Pathol 1997; 108(4):378–382.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diag-nosis and treatment of chronic lymphocytic leukemia: a report from the I nternationalWorkshop on Chronic Lymphocytic Leu-kemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111(145446–5456.
   Google Scholar
• Van Bockstaele F., Verhasselt B, Philippe J: Prognostic markers in chronic lymphocytic leukemia:A comprehensive review. Blood Rev 2008.
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, Langerak AW, Bruggemann M, et al: Design and standardization of PCR primers and protocols for detec-tion of clonal immunoglobulin and 1-cell receptor gene re-combinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17(12):2257–2317.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343(26)1910–1916.
   PubMed Web of Science ®Google Scholar
• Reddy KS: Chronic lymphocytic leukaemia profiled for progno-sis using a fluorescence in situ hybridisation panel. BrJ Haema-tol 2006; 132(6):705–722.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Villamor N, Ritgen M, et al: International stan-dardized approach for flow cytometric residual disease moni-toring in chronic lymphocytic leukaemia. Leukemia 2007; 21(5):956–964.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Kennedy B, Evans PA, et al: Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98(1):29–35.
   PubMed Web of Science ®Google Scholar
• Boyd K, Dearden CE: Alemtuzumab in the treatment of chron-ic lymphocytic lymphoma. Expert Rev Anticancer Ther 2008; 8(4):525–533.
   PubMed Web of Science ®Google Scholar
• Christian BA, Lin IS: Antibody therapy for chronic lymphocytic leukemia. Semin Hematol 2008; 45(2):95–103.
   PubMed Web of Science ®Google Scholar
• Jasionowski TM, Hartung L, Greenwood JH, Perkins SL, Bahler DW: Analysis of CD10+ hairy cell leukemia. Am] Clin Pathol 2003; 120(2):228–235.
   PubMed Web of Science ®Google Scholar
• Liu H, Ye H, Ruskone-Fourmestraux A, et al: t(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122(5)1286–1294.
   PubMed Web of Science ®Google Scholar
• Rawstron A, Barrans S, Blythe D, et al: Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br] Haematol 1999; 104(1)138–143.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Orfao A, Beksac M, et al: Report of the Europe-an Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008; 93(3):431–438.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Witzig TE, Dingli D, et al: Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005; 106(7):2276–2279.
   PubMed Web of Science ®Google Scholar
• Bench AJ, Erber WN, Follows GA, Scott MA: Molecular genetic analysis of haematological malignancies II: Mature lymphoid neoplasms. Int/ Lab Hematol 2007; 29(4):229–260.
   PubMed Web of Science ®Google Scholar
• von BH, Aifantis I, Gounari F, et al: Thymic selection revisited: how essential is it? Immunol Rev 2003; 191:62–78.
   PubMed Web of Science ®Google Scholar
• Sabnani I, Zucker MJ, Tsang P, Palekar S: granularlymphocyte proliferation in solid organ transplant recipients. Transplant Proc 2006; 38(10):3437–3440.
   PubMed Web of Science ®Google Scholar
• Lazaro E, Caubet O, Menard F, Pellegrin JL, Viallard JF: (Large granular lymphocyte leukemia). Presse Med 2007; 36(11 Pt 2)1694–1700.
   PubMed Web of Science ®Google Scholar
• Craig FE, Foon KA: Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008; 111(8):3941–3967.
   PubMed Web of Science ®Google Scholar
• Brito-Babapulle V, Catovsky D: Inversions and tandem translo-cations involving chromosome 14q11 and 14q32 in T-prolym-phocytic leukemia and 1-cell leukemias in patients with ataxia telangiectasia. Cancer Genet Cytogenet 1991; 55(1):1–9.
   PubMed Web of Science ®Google Scholar
• Sokol L, Loughran TP, Jr.: Large granular lymphocyte leukemia. Oncologist 2006; 11(3):263–273.
   PubMed Web of Science ®Google Scholar
• Mossafa H, Troussard X, Valensi F, et al: Isochromosome i(3q) and premature chromosome condensation are recurrent find-ings in chronic B-cell lymphocytosis with binucleated lympho-cytes. Leuk Lymphoma 1996; 20(3-4):267–273.
   PubMed Web of Science ®Google Scholar
• Lancry L, Roulland S, Roue G, et al: No BCL-2 protein over ex-pression but BCL-2/IgH rearrangements in B cells of patients with persistent polyclonal B-cell lymphocytosis. Hematol] 2001; 2(4):228–233.
   Google Scholar
• Adler S, Stutzman L, Sokal j, Mittelman A: Splenectomy for he-matologic depression in lymphocytic lymphoma and leukemia. Cancer 1975; 35(2):521–528.
   PubMed Web of Science ®Google Scholar
• Brito-Babapulle F: Clonal eosinophilic disorders and the hyper-eosinophilic syndrome. Blood Rev 1997; 11(3)129–145.
   PubMed Web of Science ®Google Scholar
• Roberts-Thomson PJ, Nikoloutsopoulos T, Smith AJ: Parapro-teins: a regional South Australian experience. Asian PacJAllergy Immunol 2002; 20(3):187–195.
   PubMed Web of Science ®Google Scholar
• Sipahi OR, Senol S, Arsu G, et al: Pooled analysis of 857 pub-lished adult fever of unknown origin cases in Turkey between 1990–2006. Med Sci Monit 2007; 13(7):CR318-CR322.
   PubMed Web of Science ®Google Scholar
• Ramos Rincon JM, Ramos GR, Herrero HF: (Fever of unknown origin in internal medicine. The experience of Spanish authors over 20 years). An Med lntema 1997; 14(11):585–592.
   Google Scholar